You have changed your country from  to  . Please be aware that this will change the currency in the purchasing process.

Overview

Properties

Applications

Our Abpromise guarantee covers the use of ab87438 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Notes
WB WB: Use a concentration of 1 µg/ml. Detects a band of approximately 52 kDa (predicted molecular weight: 48 kDa).Can be blocked with CLN3 peptide (ab87439).
ICC/IF ICC/IF: Use a concentration of 5 µg/ml.

Target

  • FunctionInvolved in microtubule-dependent, anterograde transport of late endosomes and lysosomes.
  • Involvement in diseaseDefects in CLN3 are the cause of neuronal ceroid lipofuscinosis type 3 (CLN3) [MIM:204200]; also known as Batten disease. A form of neuronal ceroid lipofuscinosis. Neuronal ceroid lipofuscinoses are progressive neurodegenerative, lysosomal storage diseases characterized by intracellular accumulation of autofluorescent liposomal material, and clinically by seizures, dementia, visual loss, and/or cerebral atrophy. The hallmark of CLN3 is the ultrastructural pattern of lipopigment with a fingerprint profile, which can have 3 different appearances: pure within a lysosomal residual body; in conjunction with curvilinear or rectilinear profiles; and as a small component within large membrane-bound lysosomal vacuoles. The combination of fingerprint profiles within lysosomal vacuoles is a regular feature of blood lymphocytes from patients with CLN3.
  • Sequence similaritiesBelongs to the battenin family.
  • Post-translational
    modifications
    Highly glycosylated.
    Farnesylation is important for trafficking to lysosomes.
  • Cellular localizationLysosome membrane. Late endosome.
  • Target information above from: UniProt accession Q13286 The UniProt Consortium
    The Universal Protein Resource (UniProt) in 2010
    Nucleic Acids Res. 38:D142-D148 (2010) .

    Information by UniProt
  • Database links
  • Alternative names
      Batten disease protein antibodyBattenin antibodyBTS antibody
      Ceroid lipofuscinosis neuronal 3 antibodyCeroid lipofuscinosis neuronal 3 juvenile (Batten Spielmeyer Vogt disease) antibodyCeroid lipofuscinosis neuronal 3 juvenile antibodyCLN 3 antibodyCLN3 antibodyCLN3_HUMAN antibodyJNCL antibodyMGC102840 antibodyProtein CLN3 antibody
    see all

Anti-CLN3 antibody images

  • Anti-CLN3 antibody (ab87438) at 1 µg/ml + Brain (Mouse) Tissue Lysate at 10 µg

    Secondary
    Goat polyclonal to Rabbit IgG - H&L - Pre-Adsorbed (HRP) at 1/3000 dilution
    developed using the ECL technique

    Performed under reducing conditions.

    Predicted band size : 48 kDa
    Observed band size : 52 kDa (why is the actual band size different from the predicted?)
  • ICC/IF image of ab87438 stained SHSY5Y cells. The cells were 4% formaldehyde fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab87438, 5µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

References for Anti-CLN3 antibody (ab87438)

ab87438 has not yet been referenced specifically in any publications.

Product Wall

Filter by Application

Filter by Species

Filter by Ratings

Application Immunohistochemistry (PFA perfusion fixed frozen sections)
Sample Mouse Tissue sections (Spinal cord)
Specification Spinal cord
Fixative Paraformaldehyde
Antigen retrieval step None
Permeabilization No
Username

Verified customer

Submitted Jul 29 2011

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"